Gates Foundation Joins Radiant Bio’s $35M Round for Antibody Drugs With ‘Better Grip’
Radiant Biotherapeutics’ Multabodies are antibodies engineered to offer better binding strength to their targets. The preclinical startup’s lead program goes after a cancer immunotherapy target being pursued by several biotech companies already in early clinical development.